Observational studyFrontiers in immunology2026
Characterizing immune activation in HIV-exposed but uninfected infants in the first year of life.
Observational study in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Introduction: HIV-exposed uninfected (HEU) infants experience multiple health complications compared to HIV-unexposed (HUU) infants, including immune dysregulation in the first year of life. Methods: Stored plasma samples were sourced from HEU infants enrolled in the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) protocol P1025, a prospective observational study that enrolled US pregnant people with HIV and their infants between 2002-2013, and from 3 studies that enrolled healthy HUU infants in Aurora, CO. We used the MesoScale Discovery platform to measure 16 inflammatory and regulatory biomarkers at weeks 2, 6, 24 and 48 of life. Results: In a multivariable regression analysis of 135 HEU and 51 HUU infants adjusted for sex, race/ethnicity, delivery mechanism, gestational age and birth weight, we identified higher concentrations of several biomarkers in HUU compared to HEU infants, including: IL-17A, IL-1β, IL-4, TNFα, IL-5, IL-8, MCP1, CCL22, CCL3, and CCL4. Among HEU infants, maternal CD4+ T-lymphocyte count of <200 or 200-500 copies/mL at delivery was associated with higher infant concentrations of IFNγ, IL-6, CXCL10, TNFα, CCL3, and CCL4 and maternal viral load ≥400 RNA copies/ml at delivery was associated with higher infant IL-2 and IL-10. Conclusion: We identified that HUU infants had higher concentrations of most immune biomarkers compared to HEU infants, in contrast to prior literature. We also observed that lower maternal CD4+ T-lymphocyte count and higher HIV viral load at delivery were associated with higher concentrations of several inflammatory biomarkers in HEU infants. This suggests that more advanced maternal HIV may be associated with heightened immune activation in HEU infants that persists into late infancy. These data suggest that there may be multiple subtypes of immune alterations in HEU infants, potentially existing on a spectrum spanning from immune activation to a regulatory or suppressed phenotype. Further studies are needed to determine the mechanisms through which
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.